Canaccord lowered the firm’s price target on Vericel (VCEL) to $58 from $61 and keeps a Buy rating on the shares. The firm said they posted a solid quarter, beating bottom-line metrics but slightly missing MACI expectations while Epicel generated lower revenue than anticipated, even with the highest number of Epicel biopsies in a Q since 2023.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCEL:
- Vericel’s Strong Growth Potential and Strategic Positioning Drive Buy Rating
- Vericel Corporation Reports Strong Q2 2025 Results
- Vericel’s Strong Growth and Operational Efficiency Justify Buy Rating Despite Slight Performance Miss
- Vericel reports Q2 EPS (1c), consensus (4c)
- Vericel reaffirms FY25 MACI revenue growth in low 20% range